HALOZYME THERAPEUTICS, INC.HALO财报
Nasdaq · 医疗保健 · 生物制品（不含诊断物质）
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| BlackRock, Inc. | 14.10% | 18.6M | — | 2024-01-23 |
| The Vanguard Group | 10.04% | 13.3M | ▼ -0.23pp | 2024-02-13 |
| STATE STREET CORPORATION | 5.20% | 6.6M | — | 2024-10-17 |
| Artisan Partners Limited Partnership | 5.10% | 6.7M | — | 2024-02-12 |
| OF ABOVE PERSONS | 2.10% | 2.8M | — | 2024-02-01 |
内部人交易
Net 90d: −$12.51M · buys $0 / sells $12.51M时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-06 | Helen Torley | PRESIDENT AND CEO | Option exercise | 10.0K | $12.07 | $120.7K |
| 2026-04-06 | Helen Torley | PRESIDENT AND CEO | Sell (open market) | 5.9K | $63.14 | $372.5K |
| 2026-04-06 | Helen Torley | PRESIDENT AND CEO | Sell (open market) | 4.1K | $64.02 | $262.5K |
| 2026-04-02 | Helen Torley | PRESIDENT AND CEO | Option exercise | 20.0K | $12.07 | $241.4K |
| 2026-04-02 | Helen Torley | PRESIDENT AND CEO | Sell (open market) | 15.8K | $64.06 | $1.01M |
| 2026-04-02 | Helen Torley | PRESIDENT AND CEO | Sell (open market) | 4.2K | $64.89 | $272.5K |
| 2026-04-01 | Helen Torley | PRESIDENT AND CEO | Option exercise | 20.0K | $12.07 | $241.4K |
| 2026-04-01 | Helen Torley | PRESIDENT AND CEO | Sell (open market) | 19.0K | $65.36 | $1.24M |
| 2026-04-01 | Helen Torley | PRESIDENT AND CEO | Sell (open market) | 1.0K | $65.71 | $65.7K |
| 2026-03-10 | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Option exercise | 1.5K | $33.51 | $51.8K |
1–10 of 49
第 1 页 / 共 5 页